If the scale and waistline changed after 40, insulin resistance may be part of the reason.
It should not become the whole explanation. Insulin resistance can contribute to higher blood glucose and weight gain, but weight gain, sleep disruption, medications, menopause-related body-composition change, and activity shifts can also worsen insulin resistance. [5]
The useful question is not "is insulin resistance making me gain weight?" in isolation. The useful question is which measurable risk pattern is present now, and what would change the plan.
The practical answer: it can, but usually not alone
Insulin resistance means muscle, fat, and liver cells do not respond to insulin as well as expected. The pancreas may compensate by making more insulin, and over time blood glucose can rise. NIDDK states that insulin resistance can lead to increased blood glucose and weight gain. [5]
That supports the direction many women feel in real life: weight feels easier to gain and harder to lose when glucose, waist, appetite, sleep, and energy are shifting.
But the opposite direction is also important. NIDDK lists overweight, obesity, a large waist size, inactivity, sleep apnea, polycystic ovary syndrome history, gestational diabetes history, and age 35 or older among factors tied to insulin resistance or prediabetes. [5] In other words, weight gain can be both an output of insulin resistance and one of the pressures that makes insulin resistance worse.
For a menopause-specific testing frame, see insulin resistance after menopause. For the related glucose-risk pathway, see prediabetes after menopause.
Why midlife waist gain deserves a metabolic review
Midlife weight change is not just a calorie-counting story. The pattern matters.
Waist gain, higher blood pressure, higher triglycerides, lower good cholesterol, rising fasting glucose, a higher three-month blood sugar marker, snoring, poor sleep, and medication changes can travel together. That is why a woman searching this question after 40 should usually think in terms of a metabolic review rather than a single hormone or single lab.
| Signal | Why it changes the next step |
|---|---|
| Waist gain or "apple-shaped" gain | Abdominal fat is more closely tied to metabolic risk than weight alone. See waist circumference after menopause. |
| Three-month blood sugar marker, fasting glucose, or oral glucose tolerance test in the prediabetes range | The plan moves from vague insulin-resistance concern to diabetes-prevention care. |
| High triglycerides or low good cholesterol | The risk pattern may be broader than glucose alone. |
| Snoring, poor sleep, or daytime sleepiness | Sleep apnea can worsen insulin resistance, blood pressure, and weight management. |
| Recent steroid, antipsychotic, antidepressant, insulin, or menopause-treatment change | Medication effects can change weight, appetite, glucose, or fluid balance. |
| Rapid or unexplained weight change | This needs evaluation rather than routine weight coaching. |
What the cited evidence can actually show
The stronger editorial reading is bounded:
| Evidence | What it supports | What it does not prove |
|---|---|---|
| Obesity-surgery cohort | In 190 people with obesity whose stomach tissue was examined after sleeve gastrectomy, higher insulin resistance was independently associated with more fat in the stomach wall, and the link held in a propensity-matched group of 102 patients. [1] | It is a cross-sectional finding about stomach-wall fat in people having weight-loss surgery; it does not show that insulin resistance caused body-weight gain in any reader. |
| Metformin plus insulin trial | In 26 people with type 2 diabetes treated with insulin, the group that also took metformin gained 3.8 kg over 12 months, compared with 7.5 kg with insulin alone. [2] | It does not mean metformin is automatically the right weight-loss drug for a midlife woman without diabetes or prediabetes. |
| Inflammatory-marker study | In people with type 2 diabetes, neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were independently associated with insulin resistance after adjustment. [3] | It does not make inflammation-marker ratios a consumer shortcut for diagnosing insulin resistance. |
| Prediabetes lifestyle trial (post-hoc analysis) | Among 298 adults with prediabetes who lost at least 5% of body weight, the 128 whose blood sugar regulation returned to normal had a similar drop in body mass index but a larger gain in insulin sensitivity and a larger drop in visceral fat than those who stayed prediabetic. [4] | It is a post-hoc analysis of a German trial; it shows an association and cannot show that visceral-fat loss caused the glucose change, and it does not predict any one reader's result. |
This is the honest conclusion: insulin resistance belongs in the weight-gain conversation, but it is not a stand-alone explanation.
What to check before blaming insulin resistance
Start with the tests and history that would actually change the plan.
| Question | Why it matters |
|---|---|
| Are three-month blood sugar marker, fasting plasma glucose, or oral glucose tolerance test results normal, prediabetes-range, or diabetes-range? | These results determine whether the plan is monitoring, prevention, or diabetes care. [5] |
| What are waist circumference, blood pressure, triglycerides, good cholesterol, and liver enzymes doing? | They show whether the pattern is broader metabolic syndrome, fatty-liver risk, or isolated glucose concern. |
| Did weight gain follow a medication, sleep, pain, stress, alcohol, injury, or activity change? | Treating the wrong driver wastes time and can miss a fixable cause. |
| Is there polycystic ovary syndrome history, gestational diabetes history, family history, or sleep apnea risk? | These can raise screening intensity and prevention urgency. [5] |
| Is the goal prevention, weight loss, glucose control, or body-composition maintenance? | The right lever differs by goal. A menopause weight-loss plan should protect muscle and long-term maintenance, not just lower the scale. |
Red flags that should not wait
Seek prompt medical advice for severe thirst, frequent urination, blurry vision, vomiting, confusion, fainting, chest pain, stroke symptoms, rapid unexplained weight loss, or very high home glucose.
Those are not routine "insulin resistance" clues. They can signal diabetes-range hyperglycemia, dehydration, acute cardiovascular symptoms, or another condition that needs faster evaluation.
What to ask a clinician
Ask:
- Do my three-month blood sugar marker, fasting glucose, or oral glucose tolerance test results meet normal, prediabetes, or diabetes criteria?
- Should waist circumference, triglycerides, good cholesterol, blood pressure, liver enzymes, kidney function, or sleep apnea risk change the plan?
- Could any medicine, supplement, alcohol pattern, pain limitation, or menopause treatment be affecting weight or glucose?
- If the result is prediabetes, would structured lifestyle, metformin, weight-care medication eligibility, or sleep evaluation fit me?
- If a glucagon-like peptide-1 medicine or tirzepatide is being considered, what product, dose path, side-effect plan, muscle-protection plan, and maintenance plan are realistic?
- What result would trigger follow-up sooner than the usual screening interval?
Bottom line
Insulin resistance can contribute to weight gain, and weight gain can worsen insulin resistance.
For midlife women, the safer next step is not to self-label every weight change as insulin resistance. It is to measure the risk pattern: three-month blood sugar marker, fasting glucose, or oral glucose tolerance test when appropriate; waist, blood pressure, lipids, sleep, medicines, family history, polycystic ovary syndrome or gestational diabetes history, and weight trajectory.
Once that pattern is clear, the plan can be matched to the problem: prevention, metformin discussion, sleep-apnea workup, diabetes care, glucagon-like peptide-1 or tirzepatide eligibility review, medication adjustment, strength and protein structure, or follow-up monitoring.
References
[1] Lu T, Kan J, He X, et al. Gastric Submucosal Fat Accumulation Is Associated with Insulin Resistance in Patients with Obesity. Obes Surg. 2024;34(2):534-541. doi:10.1007/s11695-023-07014-2 https://pubmed.ncbi.nlm.nih.gov/38191965/
[2] Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. 1999;42(4):406-12. doi:10.1007/s001250051172 https://pubmed.ncbi.nlm.nih.gov/10230643/
[3] Zhang Y, Liu H. Correlation between insulin resistance and the rate of neutrophils-lymphocytes, monocytes-lymphocytes, platelets-lymphocytes in type 2 diabetic patients. BMC Endocr Disord. 2024;24(1):42. doi:10.1186/s12902-024-01564-x https://pubmed.ncbi.nlm.nih.gov/38528483/
[4] Sandforth A, von Schwartzenberg RJ, Arreola EV, et al. Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). Lancet Diabetes Endocrinol. 2023;11(11):798-810. doi:10.1016/s2213-8587(23)00235-8 https://pubmed.ncbi.nlm.nih.gov/37769677/
[5] NIDDK. Insulin Resistance & Prediabetes. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance